Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)

NCT00792948 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00792948
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00792948 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 1, 2009
Completion date
January 6, 2027
Enrollment
97 (actual)
Sites
157

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, adult b acute lymphoblastic leukemia, adult b acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2); bcr-abl1, adult l1 acute lymphoblastic leukemia, adult l2 acute lymphoblastic leukemia, adult t acute lymphoblastic leukemia, recurrent adult acute lymphoblastic leukemia